Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Want to see AMLX full AI Analyst Report?
Top Page
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
Select Model
Select Model
Rating:55Neutral
Price Target:
$17.00
▼(-7.41% Downside)
Action:ReiteratedDate:04/19/26
The score is held back primarily by weak financial performance (revenue collapse to $0, ongoing losses and cash burn). Offsetting this, technicals show strong upward momentum and the latest earnings call was constructive with clear timelines and runway into 2028, though the investment case remains highly dependent on the binary Phase III outcome. Valuation is also constrained by negative earnings and no dividend support.
Positive Factors
Pivotal trial enrollment complete
Enrollment completion materially reduces operational timing risk and enables a defined regulatory timeline. With randomization/dosing nearing completion, management can focus resources on data integrity, NDA preparation and commercialization planning, improving execution visibility into 2026–2027.
Negative Factors
No commercial revenue
The absence of product revenues makes the company fully dependent on trial outcomes and external capital. Without commercialization cash flow, successful transition from clinical-stage to revenue-generating operations is binary; a failed readout would sharply impair ability to execute the growth strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal trial enrollment complete
Enrollment completion materially reduces operational timing risk and enables a defined regulatory timeline. With randomization/dosing nearing completion, management can focus resources on data integrity, NDA preparation and commercialization planning, improving execution visibility into 2026–2027.
Read all positive factors
Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.82B
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-100.00%
EPS Growth64.98%
CountryUS
Employees123
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.53
Shares Outstanding110,536,940
10 Day Avg. Volume1,415,062
30 Day Avg. Volume1,085,714
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.96
Enterprise Value/Ebitda-7.94
Forecast
1Y Price Target
$24.57Price Target Upside33.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.33
Revenue Forecast (FY)N/A
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a d...
How the Company Makes Money
null...
Amylyx Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive progress: pivotal trial enrollment complete, clear timelines (top-line Q3 2026), expanded pipeline (AMX318 nomination), AMX114 Fast Track and favorable safety, and a cash runway into 2028. Near-term cautions include a reduced cash balance versus the prior quarter, a $4M milestone payment, modeled placebo/powering conservatism, and the binary risk around the Phase III readout and subsequent regulatory/ commercialization steps. Overall, the positives — clinical progress, pipeline expansion, cost discipline, and adequate cash runway — outweigh the near-term operational and clinical uncertainties.Positive Updates
Phase III LUCIDITY Initiation and Enrollment Complete
Completed recruitment for the pivotal Phase III LUCIDITY trial of Avexatide (90 mg daily) in post-bariatric hypoglycemia (PBH); expect to randomize and dose remaining eligible participants this month and deliver top-line data in Q3 2026.
Negative Updates
Near-Term Cash Movement and Upcoming Milestone Spend
Cash balance decreased from $344M to $317M quarter-over-quarter (≈7.8% decline). Management disclosed a $4.0 million milestone payment to Gubra recognized in Q1 2026 R&D, which will increase near-term spend.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase III LUCIDITY Initiation and Enrollment Complete
Completed recruitment for the pivotal Phase III LUCIDITY trial of Avexatide (90 mg daily) in post-bariatric hypoglycemia (PBH); expect to randomize and dose remaining eligible participants this month and deliver top-line data in Q3 2026.
Read all positive updates
Company Guidance
Amylyx reiterated a clear, metric-driven plan: deliver top‑line LUCIDITY Phase III data in Q3 2026 (trial enrollment is complete and final randomizations/dosing expected this month), testing Avexatide 90 mg once daily on the FDA‑agreed Week‑16 composite of level‑2 and level‑3 hypoglycemic events (program informed by five prior trials—Phase 2 showed a 64% least‑squares mean reduction vs baseline, p=0.0031—and the Phase III was conservatively powered assuming up to a 50% placebo effect and a 35% effect size vs placebo); prepare NDA sections and regulatory readiness to move rapidly after readout with the goal of a potential 2027 commercial launch if approved; and continue portfolio development (AMX318 nominated in January with an IND target of 2027; AMX114 Fast Track with cohort‑two enrollment completing this month and biomarker data expected H1). Financially, the company ended Q4 with $317M in cash and marketable securities (down from $344M in Q3), providing an anticipated cash runway into 2028 to fund milestones, while Q4 operating expenses were $36.6M (−8% YoY) with R&D $21.2M, SG&A $15.4M, stock‑based compensation $6.4M, and a noted $4M milestone payment to Gubra to be reflected in Q1 2026 R&D.Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 87.37M | 380.79M | 22.23M | 0.00 |
| Gross Profit | -525.00K | 45.22M | 355.35M | 19.24M | 0.00 |
| EBITDA | -144.16M | -290.98M | 39.89M | -200.85M | -82.64M |
| Net Income | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
Balance Sheet | |||||
| Total Assets | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M |
| Cash, Cash Equivalents and Short-Term Investments | 316.98M | 176.50M | 371.36M | 346.94M | 96.12M |
| Total Debt | 5.96M | 1.98M | 4.24M | 6.28M | 0.00 |
| Total Liabilities | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M |
| Stockholders Equity | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M |
Cash Flow | |||||
| Free Cash Flow | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
| Operating Cash Flow | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Investing Cash Flow | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Financing Cash Flow | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
Amylyx Pharmaceuticals Inc Technical Analysis
Positive
18.36
Price Trends
14.74
Positive
14.15
Positive
12.61
Positive
Market Momentum
0.93
Negative
71.62
Negative
93.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 18.36 is above the 20-day moving average (MA) of 15.36, above the 50-day MA of 14.74, and above the 200-day MA of 12.61, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 71.62 is Negative, neither overbought nor oversold. The STOCH value of 93.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 89 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amylyx Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.89B | 23.98 | 19.84% | ― | 21.51% | 8.01% | |
70 Outperform | $2.34B | 1.67 | -76.45% | ― | 94.10% | ― | |
66 Neutral | $4.86B | 3.98 | ― | ― | -67.35% | -58.36% | |
57 Neutral | $1.92B | -7.47 | -70.76% | ― | ― | -25.27% | |
55 Neutral | $1.82B | -8.65 | -57.52% | ― | -100.00% | 64.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.53B | -2.39 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
AMLX
Amylyx Pharmaceuticals Inc
16.46
11.81
253.98%
BCRX
BioCryst
9.20
-1.07
-10.42%
DNTH
Dianthus Therapeutics
89.34
69.39
347.82%
HRMY
Harmony Biosciences Holdings
32.59
0.54
1.68%
PHVS
Pharvaris
30.02
13.19
78.37%
BHVN
Biohaven Ltd.
10.14
-9.03
-47.10%
Amylyx Pharmaceuticals Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
Positive
Mar 24, 2026
On March 24, 2026, Amylyx Pharmaceuticals updated its corporate presentation to reflect several clinical development milestones across its rare disease pipeline. The company reported completion of enrollment in the Phase 3 LUCIDITY trial of avexit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.